#PCV10
Study design: We conducted a cluster-randomised trial in Nha Trang, Vietnam comparing 4 different PCV10 schedules:

3 primary doses (3p+0)
2 primary + 1 booster (2p+1)
1 primary + 1 booster (1p+1)
Just 1 booster dose (0p+1)

following a catch-up campaign to rapidly control carriage.
November 28, 2024 at 7:59 AM
LOGAN MAILLOUX GOAL #hockey #shorts
YouTube video by Shawn Fournier
youtube.com
February 6, 2025 at 7:14 AM
CHRF's second newsletter of 2025 is here! This quarter, we share a decade of impact since the pneumococcal vaccine (PCV10): preventing pneumonia, saving lives, and making a difference.

Subscribe to our newsletter for all our latest updates: chrf.kit.com/df298b6a7f
April 30, 2025 at 3:21 PM
4/ He highlighted that this study is the first comprehensive genomic analysis of pneumococcal population in Bangladesh, demonstrating how it supports the introduction of PCV10 and showing that there has been no significant increase in cases caused by serotype 19A.
October 5, 2025 at 3:11 PM
This study examined the impact of the 10-valent pneumococcal conjugate vaccine (PCV10) on hypoxaemic and non-hypoxaemic pneumonia admissions in Kenyan children.
September 14, 2025 at 12:32 PM
The incidence of pneumococcal haemolytic uremic syndrome has increased tenfold among Swedish children in recent years. This coincides with a change in the National Immunisation program from pneumococcal #vaccine PCV13 to PCV10 that protects against fewer strains 🧪 #Pediatrics doi.org/10.1001/jama...
Pneumococcal Hemolytic Uremic Syndrome in Children in Sweden
This cohort study of children in Sweden reviewed pneumococcal hemolytic uremic syndrome cases between 2009 and 2024 for incidence rates and serotype data.
doi.org
April 22, 2025 at 11:42 AM
Vaccines are powerful tools to fight AMR. In S Africa, PCV10 and PVC13 led to an 82% drop in drug-resistant pneumococcal disease.

Rotavirus vaccine coverage in LMICs could prevent 18.3 million antibiotic-treated diarrhoea cases - just by stopping unnecessary antibiotic use.
+
May 27, 2025 at 2:52 PM
Two new research papers in The Lancet Infectious Diseases from the Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project

First paper: Global impact of PCV10 and PCV13 introduction on invasive disease

www.thelancet.com/journals/lan...
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites.
www.thelancet.com
December 18, 2024 at 1:09 PM
The introduction of the PCV10 and 13 in South Africa not only reduced the incidence of Pneumococcal disease, but also a reduction of antibiotic use and overall hospital costs
#AMR #ESPID2025
May 27, 2025 at 1:33 PM
1️⃣ – www.sciencedirect.com/science/arti...: The full direct and indirect impacts of PCV10/13 infant programs are described. High uptake of PCVs reduced overall IPD incidence in all age groups, particularly in the youngest children, despite increases in non-vaccine type IPD.
Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
Pneumococcal conjugate vaccines (PCVs) that are ten-valent (PCV10) and 13-valent (PCV13) became available in 2010. We evaluated their global impact on…
www.sciencedirect.com
December 18, 2024 at 3:04 PM
Some MGen editors picks this week

Characterisation of Strep pneumo during PCV10 introduction in Nigeria

www.microbiologyresearch.org/content/jour...
September 24, 2023 at 9:49 AM
PCV10/PCV13 cut IPD in young kids significantly, older ages moderately. Non-vaccine serotypes rose 2-3x in 6 years. Serotype 19A increased at PCV10 sites, declined at PCV13 sites.##idsky
[Articles] Global impact of ten-valent and 13-valent pneumococcal conjugate vaccines on invasive pneumococcal disease in all ages (the PSERENADE project): a global surveillance analysis
Long-term use of PCV10 or PCV13 reduced IPD substantially in young children and more moderately in older ages. Non-vaccine-type serotypes increased approximately two-fold to three-fold by 6 years after introduction of PCV10 or PCV13. Continuing serotype 19A increases at PCV10 sites and declines at PCV13 sites suggest that PCV13 use would further reduce IPD at PCV10 sites.
www.thelancet.com
March 28, 2025 at 1:30 AM
Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis | BMC Public Health

https://www.newsbeep.com/ca/111475/

This 14-year time-series analysis, encompassing both pre-PCV10 and post-PCV10 data, provides valuable insights into the …
Assessing the impact of childhood pneumococcal vaccination on pneumonia mortality in Colombia: a 14-year analysis | BMC Public Health - Canada News Beep
This 14-year time-series analysis, encompassing both pre-PCV10 and post-PCV10 data, provides valuable insights into the effect of pediatric pneumococcal
www.newsbeep.com
September 1, 2025 at 9:20 AM
2️⃣ – www.sciencedirect.com/science/arti...: The serotype distribution of IPD remaining after extensive PCV10/13 use was described. The proportion of IPD due to vaccine-type serotypes was low, and higher-valency PCVs target over half of the remaining IPD across age groups.
Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis
Widespread use of pneumococcal conjugate vaccines (PCVs) has reduced vaccine-type invasive pneumococcal disease (IPD). We describe the serotype distri…
www.sciencedirect.com
December 18, 2024 at 3:04 PM
1/ 2025 marks 10 years since Bangladesh introduced the pneumococcal conjugate vaccine (PCV10)—a monumental step in protecting children’s health across the country.We’re proud to have tracked this milestone every step of the way.
Read all of CHRF's pneumococcal papers here: chrfbd.org/blogs/7b5788...
June 5, 2025 at 3:35 PM
Population Genetic Structure of Invasive and Non-Invasive Streptococcus pneumoniae Isolates After Fifteen Years of Routine PCV10 Vaccination in Bulgaria https://pubmed.ncbi.nlm.nih.gov/41009594/
September 28, 2025 at 5:15 AM
Using an interrupted time-series analysis, the researchers found that PCV10 introduction was associated with a decrease in non-hypoxaemic pneumonia but an increase in hypoxaemic pneumonia.
September 14, 2025 at 12:32 PM
1/ The 10-valent pneumococcal conjugate vaccine (PCV10) has played a key role in reducing pneumococcal otitis media (OM) in children across Bangladesh.
Explore the full findings and their implications for child health in our latest blog:

chrfbd.org/blogs/9b1952...
April 19, 2025 at 3:55 PM
Low IPD from PCV10/PCV13 serotypes. Serotype distribution varies by vaccine and age. Higher-valency PCVs aim to cover most remaining IPD. 📉💉##idsky
[Articles] Serotype distribution of remaining invasive pneumococcal disease after extensive use of ten-valent and 13-valent pneumococcal conjugate vaccines (the PSERENADE project): a global surveillance analysis
The proportion of IPD due to serotypes included in PCVs in use was low in mature PCV10 and PCV13 settings. Serotype distribution differed between PCV10 and PCV13 sites and age groups. Higher-valency PCVs target most remaining IPD and are expected to extend impact.
www.thelancet.com
March 28, 2025 at 9:30 AM
Our latest research on the effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (PCV10) on the reduction of nasopharyngeal pneumococcal carriage in Niger is now published @thelancet.bsky.social Infectious Disease.
www.thelancet.com/journals/lan...
Effect of mass campaigns with full and fractional doses of pneumococcal conjugate vaccine (Pneumosil) on the reduction of nasopharyngeal pneumococcal carriage in Niger: a three-arm, open-label, cluster-randomised trial
Multi-age cohort campaigns had a marked effect on vaccine-type carriage and fractional-dose campaigns met non-inferiority criteria. Such campaigns should be considered in low-coverage settings, including humanitarian emergencies, to accelerate population protection.
www.thelancet.com
January 9, 2025 at 10:41 AM
Oh noooo, I'm sorry you're dealing with that! FWIW, if you haven't had the pneumonia vaccine yet (or had an older version like PCV7 or PCV10), I haven't had pneumonia once since I had the PPV15 + PPSV23 and there's decent guidance out there based on which older vaccines you got!
September 12, 2025 at 11:16 PM